Clinical trial
A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in…
NCT00976989 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT00976989 |
|---|---|
| Title | A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer |
| Official title | A Randomised, Multicentre, Multinational Phase II Study to Evaluate Pertuzumab in Combination With Trastuzumab, Given Either Concomitantly or Sequentially With Standard Anthracycline-based Chemotherapy or Concomitantly With a Non-anthracycline-based Chemotherapy Regimen, as Neoadjuvant Therapy for… |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Pertuzumab, Trastuzumab, FEC, Docetaxel, TCH |
| Enrollment | 225 |
| Start date | Nov 1, 2009 |
| Primary completion | Jun 1, 2011 |
| Completion | Jan 1, 2016 |
| First posted | Sep 15, 2009 |
| Last update posted | Feb 6, 2017 |
| Countries | Bosnia and Herzegovina, Brazil, Canada, Croatia, Germany, Greece, Italy, Mexico, New Zealand, Portugal, Romania, Serbia and 8 more |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: